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The addition of various nucleophiles to a vinyl 1,2,4-oxadiazole is described. Following optimisation, individual protocols tuned 
for the use of each specific class of reagent have been developed to allow the installation of nitrogen, sulfur, oxygen, and carbon 
nucleophiles, and leading to the preparation of a series of compounds containing the pharmaceutically important oxadiazole motif. 
Introduction 
The 1,2,4-oxadiazole motif is an important pharmacophore 
within medicinal chemistry and can be regarded as a 
bioisosteric, and metabolically stable, replacement for an ester 
unit.1 Indeed, the 1,2,4-oxadiazole is present in several 
notable drug molecules, including antitussive drugs, such as 
Perebron, 1,2 and Libexin, 2,3 as well as the serotonin agonist 
3, for the treatment of migraine,4 and L-690548, 4, for the 
treatment of Alzheimer’s disease (Figure 1).5  
 20 
<Fig 1 – Compounds 1-4 here> 
Fig. 1 Therapeutic compounds containing the 1,2,4-oxadiazole unit 
 Additionally, compounds containing the oxadiazole motif 
have been the subject of interest as novel 5-HT3 antagonists.
6 
A number of such compounds have been shown to be effective 
in the control of cancer chemotherapy-induced emesis,7 and 
evidence suggests therapeutic benefits towards migraine,8 
schizophrenia,9 and anxiety.10 Therefore, considering the 
range of potential biological applications, the formulation of 
more efficient synthetic strategies to access functionalised 
compounds containing the 1,2,4-oxadiazole motif has 
emerged as an attractive preparative goal. 
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Accessing oxadiazolylethylamines 
Recently, in efforts to access oxadiazolyl small molecules 
possessing an ethylamine motif, we envisaged a simple 
alkylation strategy, as described in Scheme 1.11 To initiate 
this process, we anticipated the construction of the oxadiazole 
by condensation of benzamidoxime 5, with lactone 6, to give 
the alcohol 7. Conversion to mesylate 8 would then allow 
alkylation of a series of amines in a parallel synthesis fashion 
to produce a library of oxadiazolylethylamines.  
 
<Scheme 1; 5 → 9 here> 
Scheme 1 Proposed route to oxadiazolylethylamines 
 In contrast to that proposed, it was observed that upon 
treatment of benzamidoxime 5, with β-lactone 6, alcohol 7 
was not isolated and instead vinyl oxadiazole 10 was obtained 
as the major product (Scheme 2).11 Nevertheless, it was 
envisaged that by employing vinyl oxadiazole 10 as an 
acceptor unit, the desired products could still be obtained by 
exploiting a conjugate addition protocol. Moreover, it was 
considered that this emerging strategy would be more 
preparatively efficient overall, with access to 10 being 
achieved more concisely than synthesis of mesylate 8. 
Moreover, the greater stability and easier handling of 10 
rendered the conjugate addition protocol more amenable to 
future parallel synthesis programmes. To this end, the scope 
of the proposed conjugate addition sequence, to gain access to 
compounds of type 9, was investigated. 
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<Scheme 2; 5 → 9 here> 
 
Scheme 2 Preparation of vinyl oxadiazole 10 and proposed access to 
oxadiazolylethylamines 
Conjugate additions to vinyl heterocycles 65 
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In a general sense, conjugate addition to vinyl heteroarenes 
represents an effective method for the direct preparation of 
pharmaceutically relevant architectures. These processes have 
been documented for several heterocyclic systems and success 
has been realised with a range of nucleophilic agents.12 With 
regards to vinyl oxadiazoles, Swain et al.,6 and later Macor et 
al.,1a described the addition of very specific nucleophiles to 
such substrates. However, these processes lacked both the 
scope of nucleophile and the preparative flexibility required 
for the generation of a diverse series of oxadiazole-derived 
adducts. We, therefore, targeted the development of simple 
and preparatively robust procedures for the conjugate addition 
of a range of nucleophiles, which have the potential to be used 
to develop libraries of substituted oxadiazoles via parallel 
synthesis strategies. 
Results and Discussion 
To begin the study, the synthesis of the convenient and bench-
stable model substrate, 3-phenyl-5-vinyl-1,2,4-oxadiazole 10, 
was altered to a more efficient and practically accessible 
reaction sequence (Scheme 3).13 Treatment of benzonitrile 
with hydroxylamine hydrochloride in the presence of base 
afforded benzamidoxime 5 in 89% yield, with this reaction 
also being readily amenable to scale-up. Acylation at ambient 
temperature delivered acrylic ester 11, which cyclised to the 
desired vinyloxadiazole 10 upon treatment with K2CO3 under 
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microwave irradiation and in near quantitative yield. Notably, 
the cyclisation step can also be performed on larger scales 
either by using a 50 mL microwave vessel (up to 25 mmol 
scale) or by conventional reflux for an extended reaction time 
(6 h) with equivalent preparative efficiency. 5 
 
<Scheme 3; synthesis of 10 here> 
Scheme 3 Improved synthesis of vinyl oxadiazole 10 
 Turning to the targeted conjugate addition reactions, 
initially we treated 10 with nBuNH2 to ascertain whether the 
desired process would proceed in the absence of any 
additional base reagent (Table 1, Entry 1). Pleasingly, a good 
yield of addition product 12a was obtained, highlighting that 
10 is a suitable acceptor unit. Furthermore, a very brief 
optimisation of reaction concentration delivered the desired 
product 12a in 98% isolated yield (Entry 2). 
10 
15 
Table 1 Optimisation of the addition process with an alkylaminea 
<Table 1 scheme here> 
Entry Equiv. Amine Conc. of 10 (M) Conc. of amine (M) Yield (%)b
1 1.05 0.2 0.21 72 
2 1.05 0.4 0.42 98 
3 2.10 0.2 0.42 89 
aSee Experimental Section. bYield refers to isolated pure products. 
 With these conditions operating efficiently, the reaction 
scope was probed by extension to a small range of primary 
and secondary amines (Table 2). Yields of addition products 
in this study were again very high, with the only 
transformation of more moderate efficiency involving the 
sterically encumbered tBuNH2 (Table 2, Entry 3), which 
provided the product 12c in 62% yield. Only minimal 
purification was required for all other entries and, generally, 
concentration of the reaction mixture was adequate to produce 
products of >95% purity, which would allow ready adoption 
of such a preparative approach for the generation of 
compound libraries. Moreover, using diethylamine as the 
nucleophilic reaction component, we were able to prepare 
Perebron 1 (Figure 1) in 99% yield (Entry 5). This establishes 
an expedient synthesis of this marketed pharmaceutical in a 
93% overall isolated yield following three steps from 
benzamidoxime 5; this compares favourably with the 
described literature method, which proceeds in 80% yield over 
two steps from the same starting compound 5.2 
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Table 2 Conjugate addition of aliphatic amines to vinyl oxadiazole 10a 
<Table 2 scheme here> 
Entry Amine Product Yield (%)b 
1 nBuNH2 12a 98 
2 iBuNH2 12b 99 
3 tBuNH2 12c 62 
4 BnNH2 12d 98 
5 Et2NH 1 99 
a See Experimental Section. bYield refers to isolated  pure products. 
 While simple alkyl amines participated efficiently in the 
desired addition process, installation of aniline in a similar 
fashion proved to be more preparatively challenging. Initial 
reactions using the optimum conditions for the aliphatic amine 
substrates failed to deliver any of the desired product (Table 
3, Entry 1) and increasing the temperature to reflux in DCM 
for a more extended reaction period led to no improvement 
(Entry 2). When moving to heating in a higher boiling solvent 
(PhMe) for 48 h, a low conversion to product was obtained 
(Entry 3), and a slight enhancement was noted when a protic 
solvent (nPrOH) was employed at reflux (Entry 4). Despite 
this, the reaction yields obtained here were less than 
acceptable. Furthermore, addition of a series of base species 
(NaH, K2CO3, Cs2CO3), as potential reaction promoters, 
unfortunately, provided no improvements in the efficiency of 
the desired addition process. 
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Table 3 Initial conjugate addition reactions using aniline 
<Table 3 scheme here> 
Entry Conditions Yield (%)a 
1 DCM, r.t., 20 h 0 
2 DCM, reflux, 48 h 0 
3 PhMe, reflux, 48 h 5 
4 nPrOH, reflux, 48 h 14 
aYield refers to isolated  pure products. 
 At this point, an alternative strategy was considered, 
whereby the electrophilicity of the vinyl oxadiazole would be 
augmented by the addition of a Brönsted or Lewis acid. As 
shown in Table 4, this approach clearly had the intended 
effect of enhancing the acceptor capabilities of the oxadiazole 
unit. Use of Brönsted acids delivered the desired addition 
product in modest yields, with the use of (the higher boiling) 
propionic acid in n-propanol being optimum (Table 4, Entry 
3). Several reactions were also performed under microwave 
irradiation. Whilst moderate yields were also delivered in 
these cases, with a Brönsted acid additive (Entries 4-7), no 
improvement was observed over the results achievable using 
conventional heating methods. In contrast, specific Lewis acid 
promotion did, indeed, deliver further improvements to the 
targeted addition process with aryl amines. When using 
BF3.OEt2 as an additive, the most efficient addition reaction 
with aniline in this series was obtained with a 55% isolated 
yield of 12e (Entry 9).  
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Table 4 Use of Brönsted and Lewis acids in the addition of PhNH2 to 10a 
<Table 4 scheme here> 
Entry Additiveb Conditions Yield (%)c 
1 AcOH MeOH, reflux, 20 h 34 
2 AcOH nPrOH, reflux, 20 h 35 
3 EtCO2H nPrOH, reflux, 20 h 38 
4 ----- MeCN, mw, 188oC, 1 h 0 
5 AcOH MeCN, mw, 188oC, 1 h 26 
6 ----- nPrOH, mw, 200oC, 1 h 0 
7 AcOH nPrOH, mw, 200oC, 1 h 30 
8 LiClO4 MeOH, reflux, 20 h 25 
9 BF3.OEt2 THF, reflux, 20 h 55 
aSee Experimental Section. b1.05 equiv. cYield refers to isolated pure 
products. 
 Having formulated conditions for the use of both alkyl and 
aryl amines with good to excellent levels of efficiency, 
attention turned to the delivery of alternative nucleophilic 
species. Firstly, sulfur-based nucleophiles are known to 
participate effectively in conjugate addition processes and, as 
such, we attempted the addition of a simple alkyl thiol to the 
80 
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vinyloxadiazole 10 (Table 5). Under the standard conditions 
used with alkyl amines at either room temperature or at reflux 
in DCM, no product was obtained (Table 5, Entries 1 and 2). 
Moving to an additive study, a similar reactivity profile was 
observed as with aniline, in which added base reagents 
provided only very low conversions to product (Entries 3-5). 
On the other hand, the addition of HCl was found to deliver a 
very good yield of the desired sulfide 13a (Entry 7). 
5 
10 
15 
 A similar study was subsequently conducted with 
thiophenol. In this case, it was found that an excellent yield of 
the intended product could be obtained simply by heating in 
DCM (Table 6, Entry 2). For completeness, an additive study 
was performed which demonstrated that the presence of acid 
was detrimental to the reaction (Entries 6 and 7). In contrast, 
the presence of base provided a moderate preparative 
advantage by allowing good yields of the aryl thiol addition 
product to be obtained at lower (ambient) temperatures 
(Entries 3-5). 
  
Table 5 Screening of conditions for the addition of nBuSH to 10a 20 
<Table 5 scheme here> 
Entry Additive Conditions Yield (%)b 
1 ----- DCM, r.t., 20 h 0 
2 ----- DCM, reflux, 20 h 0 
3 NaH (1.2 equiv.) THF, reflux, 20 h 2 
4 K2CO3 (1.2 equiv.) THF, reflux, 20 h 0 
5 K2CO3 (1.2 equiv.) DMF, 80oC, 20 h 8 
6 AcOH (1.05 equiv.) MeOH, reflux, 20 h 6 
7 HCl (1.05 equiv.) MeOH, reflux, 20 h 88 
aSee Experimental Section. bYield refers to isolated  pure products. 
   
Table 6 Screening of conditions for the addition of PhSH to 10a 
<Table 6 scheme here> 
Entry Additive Conditions Yield (%)b 
1 ----- DCM, r.t., 40 h 50 
2 ----- DCM, reflux, 20 h 94 
3 NaH (1.2 equiv.) THF, r.t., 24 h 79 
4 K2CO3 (1.2 equiv.) THF, r.t., 24 h 85 
5 Cs2CO3 (1.2 equiv.) THF, r.t., 24 h 58 
6 AcOH (1.05 equiv.) MeOH, reflux, 20 h 23 
7 HCl (1.05 equiv.) MeOH, reflux, 20 h 40 
aSee Experimental Section. bYield refers to isolated  pure products. 
 To build on the success of the emerging nucleophile-
specific addition methods which had been developed to this 
stage for vinyloxadiazole, we next sought to install oxygen-
based nucleophiles in a conjugate fashion. As shown in Table 
7, successful addition of alcohols was achievable in 
acceptable yields either in the presence of basic (Entry 1) or 
acidic additives (Entry 2). Unfortunately, regardless of the 
conditions applied (with acid/base additives and over various 
temperature/time studies), phenol did not successfully 
participate in the desired addition reaction. 
25 
30 
Table 7 Addition of alcohols to 10a 35 
<Table 7 here> 
Entry R  Additive Conditions Yield (%)b
1 Et NaH (1.2 equiv.) EtOH, r.t., 20 h 78 
2 nPr HCl (1.05 equiv.) nPrOH, reflux, 20 h 63 
aSee Experimental Section. bYield refers to isolated  pure products. 
 Finally, we turned briefly to the use of carbon-based 
nucleophiles with vinyloxadiazole 10 (Table 8). Pleasingly, 
addition of diethyl malonate proceeded to deliver 15a in 51% 
yield, using NaH as the base reagent (Entry 1). Additionally, 
use of the more challenging butyl cuprate delivered the 
desired product 15b in a moderate 40% yield (Entry 2). 
Further endeavours, employing a range of additives and 
conditions, did not improve upon the result shown for this 
latter process. 
40 
45 
Table 8 Addition of carbon-based nucleophiles to 10a 
<Table 8 scheme here> 
Entry Nucleophile Product Conditions Yield (%)b
1 H2C(CO2Et)2 (1.05 equiv.) 15a 
NaH (1.2 equiv.), 
THF, r.t., 5 h 51 
2 nBu2CuLi (1.2 equiv.) 15b Et2O, -78oC, 2 h 40 
aSee Experimental Section. bYield refers to isolated  pure products. 
Conclusions 
In conclusion, after a broad screening process, we have 
developed a series of practically-convenient conditions which 
allow for the effective conjugate addition of a range of 
nucleophiles to a vinyl 1,2,4-oxadiazole. In particular, the 
individual protocols are tuned for the use of each specific 
class of nucleophile and enable the efficient introduction of 
alkylamines and alkyl- and aryl thiols without the requirement 
for any appreciable purification protocols and which will be 
readily applicable within parallel synthesis programmes. 
Additionally, further specific conditions for the introduction 
of aryl amines, aliphatic alcohols, and carbon-based 
nucleophiles have also been established which, despite being 
somewhat less efficient, have the potential for ready adoption 
within medicinal chemistry or agrochemical environments. 
Overall, by employment of a common heterocyclic core and a 
spectrum of suitable nucleophiles, these procedures will allow 
the flexible and effective production of arrays of compounds 
containing the biologically significant oxadiazole motif. 
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Experimental 
All reactions were carried out using conventional glassware 
and procedures. Starting materials and solvents were used as 
obtained from commercial suppliers without further 
purification. For air sensitive reactions, standard protocols 
were employed using dry solvents and under a N2 atmosphere. 
Solutions, solvents and liquid reagents were added via 
syringe. Microwave reactions were performed in a CEM 
Discover dedicated microwave reactor in sealed tubes. Light 
petroleum refers to the fraction of b.p. 30-40°C. Thin layer 
chromatography was carried out using Camlab silica plates 
coated with indicator UV254. These were analysed using a 
Mineralight UVGL-25 lamp or developed using vanillin or 
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potassium permanganate solutions. Flash column 
chromatography was carried out using Prolabo silica gel (230-
400 mesh). IR spectra were obtained on a Perkin Elmer 
Spectrum One machine.
 1H and 13C NMR spectra were 
recorded on a Bruker DPX 400 spectrometer at 400 MHz and 
100 MHz, respectively, or a Bruker DRX 500 spectrometer at 
500 MHz and 125 MHz, respectively. Chemical shifts are 
reported in ppm.  Coupling constants are reported in Hz. 
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Synthesis of Vinyloxadiazole, 10. 
a) Preparation of 5: A solution of benzonitrile (1 equiv., 25 mmol, 
2.55 mL), hydroxylamine hydrochloride (2 equiv., 50 mmol, 
3.475 g) and iPr2NEt (2 equiv., 50 mmol, 8.76 mL) in EtOH (250 
mL) was heated at 80oC for 18 h. The solution was cooled to 
room temperature and the solvent removed in vacuo. The residue 
was partitioned between DCM (100 mL) and H2O (100 mL) and 
the organic phase separated. The aqueous phase was further 
extracted with DCM (3 x 100 mL) and the organic extracts were 
combined. After drying (MgSO4) and filtering, the organic 
solution was concentrated to afford 5 as a viscous oil (3.04 g, 
89%). 
b) Preparation of 11: To a solution of 5 (1 equiv., 20.9 mmol, 2.84 
g) in DCM (230 mL) was added acryloyl chloride (1.2 equiv., 25 
mmol, 2.03 mL). The mixture was stirred for 3 h at room 
temperature before quenching with an aq. solution of NaHCO3 
(100 mL). The organic layer was separated and the aqueous layer 
was further extracted with DCM (2 x 50 mL). The organic 
extracts were combined, dried (MgSO4), filtered, and 
concentrated to afford 11 as an off-white solid (3.856 g, 97%). 
c) Preparation of 10: 
i) Microwave conditions: A microwave tube charged with 11 (1 
equiv., 2.63 mmol, 0.5 g), 1,4-dioxane (5 mL) and K2CO3 (2 
equiv., 5.26 mmol, 0.726 g) was heated at 120oC for 20 min. in a 
microwave reactor. The mixture was allowed to cool before being 
filtered and concentrated to a residue which was purified by 
column chromatography eluting with 10% Et2O/light petroleum 
to afford 10 as a colourless oil (0.439 g, 97%). 
ii) Reflux conditions: A solution of 11 (1 equiv., 2.63 mmol, 0.5 
g), 1,4-dioxane (5 mL) and K2CO3 (2 equiv., 5.26 mmol, 0.726 g) 
was heated at 120oC for 6 h. The mixture was allowed to cool 
before being filtered and concentrated to a residue which was 
purified by column chromatography eluting with 10% Et2O/light 
petroleum to afford 10 as a colourless oil (0.453 g, 100%). 
 
Conjugate addition of alkylamines to 10. To a solution of 10 (1 
equiv., 1 mmol, 172 mg) in DCM (2.5 mL) was added the amine 
(1.05 equiv., 1.05 mmol). The reaction mixture was then stirred at 
room temperature for 20 h before concentrating in vacuo to a 
residue which was purified by column chromatography eluting 
with 10% Et2O/light petroleum to afford the desired addition 
product. For example, using nBuNH2 (1.05 mmol, 0.101 mL) 
gave 12a as a pale yellow oil (240 mg, 98%). 
 
Conjugate addition of PhNH2 to 10. To a solution of 10 (1 
equiv., 1 mmol, 172 mg) in THF (2.5 mL) was added aniline 
(1.05 equiv., 1.05 mmol, 0.096 mL) and BF3.OEt2 (1.05 equiv., 
1.05 mmol, 0.133 mL). The reaction mixture was then refluxed 
for 20 h before cooling to room temperature and quenching with 
NaHCO3 aq. solution (5 mL). The mixture was then extracted 
with DCM (4 x 15 mL). The organic extracts were combined, 
dried (MgSO4), filtered, and concentrated in vacuo to a residue 
which was purified by column chromatography eluting with 10%-
50% Et2O/light petroleum to afford 12e as a yellow/brown solid 
(145 mg, 55%). 
 
Conjugate addition of nBuSH to 10. To a solution of 10 (1 
equiv., 1 mmol, 172 mg) in MeOH (2.5 mL) was added nBuSH 
(1.05 equiv., 1.05 mmol, 0.113 mL) and HCl (1 M solution in 
Et2O, 1.05 equiv., 1.05 mmol, 1.05 mL). The reaction mixture 
was then refluxed for 20 h before cooling to room temperature 
and quenching with NaHCO3 aq. solution (5 mL). The mixture 
was then extracted with DCM (4 x 15 mL). The organic extracts 
were combined, dried (MgSO4), filtered, and concentrated in 
vacuo to a residue which was purified by column 
chromatography eluting with 10% Et2O/light petroleum to afford 
13a as a yellow oil (232 mg, 88%). 
 
Conjugate addition of PhSH to 10. To a solution of 10 (1 equiv., 
1 mmol, 172 mg) in DCM (2.5 mL) was added PhSH (1.05 
equiv., 1.05 mmol, 0.108 mL). The reaction mixture was then 
refluxed for 24 h before concentrating in vacuo to a residue 
which was purified by column chromatography eluting with 10% 
Et2O/light petroleum to afford 13b as a yellow oil (265 mg, 94%). 
 
Conjugate addition of alcohols to 10. 
i) Using NaH: To a solution of 10 (1 equiv., 1 mmol, 172 mg) in 
EtOH (2.5 mL) was added NaH (60% dispersion in mineral oil, 
1.2 equiv., 1.2 mmol, 48 mg). The reaction mixture was then 
stirred under N2 for 20 h before quenching with NaHCO3 aq. 
solution (5 mL). The mixture was then extracted with DCM (4 x 
15 mL). The organic extracts were combined, dried (MgSO4), 
filtered, and concentrated in vacuo to a residue which was 
purified by column chromatography eluting with 10% Et2O/light 
petroleum to afford 14a as a colourless oil (170 mg, 78%). 
ii) Using HCl: To a solution of 10 (1 equiv., 1 mmol, 172 mg) in 
nPrOH (2.5 mL) was added HCl (1 M solution in Et2O, 1.05 
equiv., 1.05 mmol, 1.05 mL). The reaction mixture was then 
refluxed for 20 h before cooling to room temperature and 
quenching with NaHCO3 aq. solution (5 mL). The mixture was 
then extracted with DCM (4 x 15 mL). The organic extracts were 
combined, dried (MgSO4), filtered, and concentrated in vacuo to 
a residue which was purified by column chromatography eluting 
with 10% Et2O/light petroleum to afford 14b as a yellow oil (146 
mg, 63%). 
 
Conjugate addition of carbon-based nucleophiles to 10. 
i) Using diethyl malonate and NaH: To a solution of 10 (1 equiv., 
1 mmol, 172 mg) in THF (2.5 mL) was added NaH (60% 
dispersion in mineral oil, 1.2 equiv., 1.2 mmol, 48 mg). The 
mixture was then stirred for 5 h under N2 before quenching with 
NaHCO3 aq. solution (5 mL). The mixture was then extracted 
with DCM (4 x 15 mL). The organic extracts were combined, 
dried (MgSO4), filtered, and concentrated in vacuo to a residue 
which was purified by column chromatography eluting with 10% 
Et2O/light petroleum to afford 15a as a colourless oil (170 mg, 
51%). 
ii) Using nBu2CuLi: To a solution of CuI (1.2 equiv., 1.2 mmol, 
229 mg) in dry Et2O (10 mL) at -78
oC was added nBuLi (2.38 M 
in hexane, 2.4 equiv., 2.4 mmol, 1.01 mL) drop-wise over 5 min. 
The mixture was stirred at -78oC for 1 h before the addition of a 
solution of 10 (1 equiv., 1 mmol, 172 mg) in Et2O (2 mL) over 5 
min. The mixture was then stirred at -78oC for 2 h before 
quenching with H2O (10 mL). The mixture was allowed to warm 
to room temperature before extraction with Et2O (3 x 15 mL). 
The organic extracts were combined, dried (MgSO4), filtered, and 
concentrated in vacuo to a residue which was purified by column 
chromatography eluting with 10% Et2O/light petroleum to afford 
15b as a colourless oil (93 mg, 40%). 
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Compound data.      
Compound 5: Viscous colourless oil; νmax (CH2Cl2)/cm-1 3598, 
3519, 3410, 2924, 1647, 1581; δH (400 MHz, CDCl3) 8.52 (1H, 
s,), 7.65 (2H, dd, J 9.8, 2.8), 7.45-7.38 (3H, m), 4.90 (2H, s); δC 
(100 MHz, CDCl3) 152.6, 132.5, 130.0, 128.7, 125.9; Anal. 
Calcd. for C7H8N2O requires C, 61.75%; H, 5.92; N, 20.58%. 
Found: C, 62.65; H, 5.85; N, 20.58%; HRMS (ES) Found [M + 
H]+ 137.0708, C7H9N2O requires 137.0709. 
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Compound 10: Colourless oil; νmax (CH2Cl2)/cm-1 3074, 2960, 
1648, 1593, 1563, 1542; δH (400 MHz, CDCl3) 8.11 (2H, dd, J 
9.8, 2.7), 7.55-7.47 (3H, m), 6.78 (1H, dd, J 17.7, 11.0), 6.61 (1H, 
dd, J 17.7, 0.9), 6.01 (1H, dd, J 11.0, 0.9); δC (100 MHz, CDCl3) 
174.5, 168.7, 131.2, 128.9, 128.7, 127.5, 126.8, 120.6; Anal. 
Calcd. for C10H8N2O requires C, 69.76%; H, 4.68%; N, 16.27%. 
Found: C, 69.78%; H, 4.41%; N, 16.42%; HRMS (ES) Found [M 
+ H]+ 173.0709, C10H9N2O requires 173.0709. 
Compound 11: Off-white solid; Mp 69-70oC; νmax (CH2Cl2)/cm-1 
3528, 3421, 1701, 1634; δH (400 MHz, CDCl3) 7.73 (2H, dd, J 
7.9, 1.5), 7.52-7.41 (3H, m), 6.56 (1H, dd, J 17.3, 1.0), 6.32 (1H, 
dd, J 17.3, 10.5), 5.92 (1H, dd, J 10.5, 1.0), 5.11 (2H, s); δC (100 
MHz, CDCl3) 163.9, 156.8, 131.4, 131.1, 131.0, 128.7, 126.8, 
126.7; Anal. Calcd. for C10H10N2O2 requires C, 63.15%; H, 
5.30%; N, 14.73%. Found: C, 63.11%; H, 5.22%; N, 14.75%; 
HRMS (ES) Found [M + H]+ 191.0814, C10H11N2O2 requires 
191.0815. 
Compound 12a: Pale yellow oil; νmax (CH2Cl2)/cm-1 3692, 2960, 
2931, 2861, 1595, 1571, 1476, 1447; δH (400 MHz, CDCl3) 8.08 
(2H, dd, J 7.5, 2.3), 7.51-7.46 (3H, m), 3.51 (4H, s), 2.68 (2H, t, J 
7.2), 1.50 (2H, quintet, J 7.3), 1.46 (3H, sextet, J 7.3), 0.93 (3H, t, 
J 7.3); δC (100 MHz, CDCl3) 178.8, 168.5, 131.1, 129.0, 127.6, 
127.1, 49.4, 46.4, 32.4, 27.6, 20.6, 14.2; Anal. Calcd. for 
C14H19N3O requires C, 68.54%; H, 7.81%; N, 17.30%. Found: C, 
68.25%; H, 7.75%; N, 17.34%; HRMS (ES) Found [M + H]+ 
246.1599, C14H20N3O requires 246.1601. 
Compound 12b: Pale yellow oil; νmax (CH2Cl2)/cm-1 3692, 2958, 
2842, 1595, 1571, 1476, 1447; δH (400 MHz, CDCl3) 8.08 (2H, 
dd, J 5.6, 2.3), 7.53-7.45 (3H, m), 3.14 (4H, s), 2.49 (2H, d, J 
6.8), 1.76 (1H, septet, J 6.7), 1.44 (1H, s), 0.92 (6H, d, J 6.7); δC 
(100 MHz, CDCl3) 178.8, 168.4, 131.3, 129.0, 127.6, 127.1, 57.7, 
46.5, 28.5, 27.6, 20.8; Anal. Calcd. for C14H19N3O requires C, 
68.54%; H, 7.81%; N, 17.30%. Found: C, 68.18%; H, 7.61%; N, 
17.50%; HRMS (ES) Found [M + H]+ 246.1600, C14H20N3O 
requires 246.1601. 
Compound 12c:14 Pale yellow oil; νmax (CH2Cl2)/cm-1 3692, 2969, 
2867, 1595, 1571, 1477, 1447; δH (400 MHz, CDCl3) 8.08 (2H, 
dd, J 7.3, 2.0), 7.51-7.46 (3H, m), 3.10 (4H, s), 1.14 (9H, s); δC 
(125 MHz, CDCl3) 178.8, 168.2, 131.1, 128.8, 127.4, 126.9, 50.6, 
39.5, 29.0, 28.6. 
Compound 12d: Pale yellow oil; νmax (CH2Cl2)/cm-1 3693, 3029, 
2926, 2850, 1595, 1571, 1477, 1447; δH (400 MHz, CDCl3) 8.08 
(2H, dd, J 7.6, 1.9), 7.53-7.47 (3H, m), 7.34 (4H, d, J 4.3), 7.27 
(1H, m), 3.87 (2H, s), 3.17 (4H, s); δC (100 MHz, CDCl3) 178.7, 
168.5, 140.1, 131.3, 129.0, 128.6, 128.2, 127.6, 127.2, 127.0, 
53.6, 45.7, 27.6; Anal. Calcd. for C17H17N3O requires C, 73.10%; 
H, 6.13%; N, 15.04%. Found: C, 72.86%; H, 6.06%; N, 15.16%; 
HRMS (ES) Found [M + H]+ 280.1443, C17H18N3O requires 
280.1444. 
Compound 1:2 Pale yellow oil; νmax (CH2Cl2)/cm-1 2937, 2974, 
2876, 2821, 1595, 1571, 1476, 1447; δH (500 MHz, CDCl3) 8.08 
(2H, dd, J 7.3, 2.1), 7.50-7.46 (3H, m), 3.11-3.07 (2H, m), 3.04-
3.01 (2H, m), 2.59 (4H, q, J 7.2), 1.06 (6H, t, J 7.1); δC (125 
MHz, CDCl3) 178.9, 168.3, 131.0, 128.8, 127.4, 127.0, 49.6, 
46.9, 25.0, 12.0. 
Compound 12e: Yellow-brown solid; Mp 83-84oC; νmax 
(CH2Cl2)/cm
-1 3437, 3044, 2982, 2830, 1603, 1571, 1551, 1508, 
1439; δH (400 MHz, CDCl3) 8.10 (2H, dd, J 7.6, 1.9), 7.53-7.48 
(3H, m), 7.22 (2H, t, J 7.9), 6.77 (1H, t, J 7.3), 6.69 (2H, d, J 
7.7), 4.17 (1H, s), 3.74 (2H, t, J 6.5), 3.26 (2H, t, J 6.5); δC (100 
MHz, CDCl3) 178.5, 168.9, 147.6, 131.8, 130.0, 129.4, 128.0, 
127.3, 118.8, 113.8, 41.2, 27.2; HRMS (ES) Found [M + H]+ 
266.1286, C16H16N3O requires 266.1288. 
Compound 13a: Yellow oil; νmax (CH2Cl2)/cm-1 3056, 2981, 2874, 
2831, 1594, 1571, 1551, 1443; δH (500 MHz, CDCl3) 8.08 (2H, 
dd, J 7.7, 1.9), 7.53-7.46 (3H, m), 3.24 (2H, t, J 7.7), 3.03 (2H, t, 
J 7.6), 2.59 (2H, t, J 7.4), 1.60 (2H, quintet, J 7.4), 1.42 (2H, 
sextet, J 7.4), 0.93 (3H, t, J 7.3); δC (125 MHz, CDCl3) 178.1, 
168.4, 131.2, 128.8, 127.4, 126.8, 31.9, 31.6, 28.5, 27.7, 21.9, 
13.6; HRMS (ES) Found [M + H]+ 263.1214, C14H19N2OS 
requires 263.1213. 
Compound 13b: Yellow oil; νmax (CH2Cl2)/cm-1 3045, 2989, 
2831, 1594, 1571, 1551, 1443; δH (400 MHz, CDCl3) 8.06 (2H, 
dd, J 6.9, 1.4), 7.53-7.47 (3H, m), 7.44 (2H, dd, J 6.9, 1.4), 7.33 
(2H, t, J 7.4), 7.26 (1H, t, J 7.3), 3.42 (2H, t, J 7.5), 3.25 (2H, t, J 
7.4); δC (100 MHz, CDCl3) 178.3, 168.9, 134.8, 131.7, 131.4, 
129.8, 129.4, 128.0, 127.7, 127.3, 31.4, 27.8; Anal. Calcd. for 
C16H14N2OS requires C, 68.06%; H, 5.00%; N, 9.92%. Found: C, 
67.81%; H, 5.00%; N, 9.81%; HRMS (ES) Found [M + H]+ 
283.0901, C16H15N2OS requires 283.0900. 
Compound 14a: Colourless oil; νmax (CH2Cl2)/cm-1 3055, 2980, 
2875, 2831, 1595, 1572, 1551, 1477, 1443; δH (400 MHz, CDCl3) 
8.06 (2H, dd, J 7.5, 2.2), 7.51-7.43 (3H, m), 3.91 (2H, t, J 6.7), 
3.54 (2H, q, J 7.0), 3.22 (2H, t, J 6.7), 1.19 (3H, t, J 7.0); δC (100 
MHz, CDCl3) 177.8, 168.5, 131.2, 129.0, 127.6, 127.1, 66.7, 
66.6, 28.0, 15.2; Anal. Calcd. for C12H14N2O2 requires C, 
66.04%; H, 6.47%; N, 12.84%. Found: C, 65.86%; H, 6.31%; N, 
12.86%; HRMS (ES) Found [M + H]+ 219.1129, C12H15N2O2 
requires 219.1128. 
Compound 14b: Yellow oil; νmax (CH2Cl2)/cm-1 3076, 2981, 
2877, 2831, 1596, 1572, 1551, 1528, 1443; δH (500 MHz, CDCl3) 
8.09 (2H, dd, J 6.8, 1.7), 7.52-7.46 (3H, m), 3.92 (2H, t, J 6.6), 
3.46 (2H, t, J 6.6), 3.23 (2H, t, J 6.6), 1.59 (2H, sextet, J 7.1), 
0.90 (3H, t, J 7.4); δC (125 MHz, CDCl3) 177.7, 168.3, 131.1, 
128.8, 127.4, 126.9, 72.9, 66.7, 27.8, 22.7, 10.5; HRMS (ES) 
Found [M + H]+ 233.1285, C13H17N2O2 requires 233.1285. 
Compound 15a: Colourless oil; νmax (CH2Cl2)/cm-1 3055, 2980, 
2874, 2831, 1752, 1595, 1572, 1477, 1443; δH (400 MHz, CDCl3) 
8.08 (2H, dd, J 7.7, 1.9), 7.53-7.45 (3H, m), 4.26-4.20 (4H, q, J 
7.2), 3.57 (1H, t, J 7.3), 3.07 (2H, t, J 7.6), 2.49 (2H, q, J 7.5), 
1.29 (6H, t, J 7.1); δC (100 MHz, CDCl3) 178.8, 170.3, 168.8, 
131.4, 129.0, 127.6, 127.0, 61.9, 50.9, 25.4, 24.4, 14.3; Anal. 
Calcd. for C17H20N2O5 requires C, 61.44%; H, 6.07%; N, 8.43%). 
Found: C, 61.56%; H, 5.88%; N, 8.58%; HRMS (ES) Found [M 
+ H]+ 333.1443, C17H21N2O5 requires 333.1445. 
Compound 15b: Colourless oil; νmax (CH2Cl2)/cm-1 3065, 2982, 
2860, 2831, 1594, 1570, 1528, 1425; δH (400 MHz, CDCl3) 8.08 
(2H, dd, J 7.4, 2.1), 7.53-7.46 (3H, m), 2.95 (2H, t, J 7.6), 1.88 
(2H, quintet, J 7.6), 1.46-1.40 (2H, m), 1.36-1.32 (4H, m), 0.89 
(3H, t, J 7.3); δC (100 MHz, CDCl3) 180.3, 168.5, 131.2, 129.0, 
127.6, 127.2, 31.5, 28.9, 26.9(2), 22.6, 14.2; HRMS (ES) Found 
[M + H]+ 231.1491, C14H19N2O requires 231.1492. 
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